ACT DMD Update with PTC (February 2014) On February 5, 2014, Dr. Robert Spiegel, Chief Medical Officer at PTC Therapeutics, presented an update about PTC’s Phase 3 study of ataluren, now known as the Ataluren Confirmatory Trial in DMD (ACT DMD). Research & Clinical Trial Webinars,Webinars 11 years ago You may also like 50:18 Roche/Genentech Anti-Myostatin Adnectin RG6206 in Duchenne (May 2018) 6 years ago Research & Clinical Trial Webinars,Webinars 49:43 NS Pharma’s Exon 53 Skipping Program Update (April 2018) 7 years ago Research & Clinical Trial Webinars,Webinars 1:01:32 Gene Therapy: A Closer Look (March 2018) 7 years ago Research & Clinical Trial Webinars,Webinars gene therapy 1:02:50 Pulmonary Care in Adults with Duchenne (March 2018) 7 years ago Care Webinars,Webinars 50:27 Positive Data from Summit’s PhaseOUT DMD Ezutromid Clinical Trial (February 2018) 7 years ago Research & Clinical Trial Webinars,Webinars 53:55 Italfarmaco Provides Givinostat Update (January 2018) 7 years ago Research & Clinical Trial Webinars,Webinars 1:05:47 Understanding Gene Therapy, Part 3 – Galgt2 and Dup2 (December 2017) 7 years ago Research & Clinical Trial Webinars,Webinars gene therapy 50:36 Capricor Therapeutics’ HOPE-Duchenne Clinical Trial (November 2017) 7 years ago Research & Clinical Trial Webinars,Webinars «1…1516171819…25»Page 17 of 25
by: Parent Project Muscular Dystrophy
